Abstract
Current tuberculosis (TB) treatment is based on a combination of drugs that were developed mostly in the central decades of the last century. Cure rates are high for drug sensitive strains of Mycobacterium tuberculosis (M. tb) when the recommended complex and lengthy treatment protocols are adhered to. However the difficulty in correctly prescribing and adhering to these protocols, the emergence of M. tb strains resistant to multiple drugs, and drug-drug interactions that interfere with optimal treatment of HIV and TB coinfected patients have generated a pressing need for improved TB therapies. Together with the ominous global burden of TB, these shortcomings of current treatment have contributed to a renewed interest in the development of improved drugs and protocols for the treatment of tuberculosis. This article highlights hurdles related to the optimized use of existing drugs and challenges related to the development of novel, improved products, focusing in particular on aspects inherent in TB drug clinical development. Concluding comments propose processes for more efficient development of new TB therapies.
Keywords: Tuberculosis (TB) drug development, pipeline, fluoroquinolones, nitroimidazoles, rifamycins, clinical trials
Infectious Disorders - Drug Targets
Title: Challenges Associated with Current and Future TB Treatment
Volume: 7 Issue: 2
Author(s): M. Laurenzi, A. Ginsberg and M. Spigelman
Affiliation:
Keywords: Tuberculosis (TB) drug development, pipeline, fluoroquinolones, nitroimidazoles, rifamycins, clinical trials
Abstract: Current tuberculosis (TB) treatment is based on a combination of drugs that were developed mostly in the central decades of the last century. Cure rates are high for drug sensitive strains of Mycobacterium tuberculosis (M. tb) when the recommended complex and lengthy treatment protocols are adhered to. However the difficulty in correctly prescribing and adhering to these protocols, the emergence of M. tb strains resistant to multiple drugs, and drug-drug interactions that interfere with optimal treatment of HIV and TB coinfected patients have generated a pressing need for improved TB therapies. Together with the ominous global burden of TB, these shortcomings of current treatment have contributed to a renewed interest in the development of improved drugs and protocols for the treatment of tuberculosis. This article highlights hurdles related to the optimized use of existing drugs and challenges related to the development of novel, improved products, focusing in particular on aspects inherent in TB drug clinical development. Concluding comments propose processes for more efficient development of new TB therapies.
Export Options
About this article
Cite this article as:
M. Laurenzi , A. Ginsberg and M. Spigelman , Challenges Associated with Current and Future TB Treatment, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001817
DOI https://dx.doi.org/10.2174/187152607781001817 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Anti-Infective Drug Discovery P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Similarities/Dissimilarities Analysis of Protein Sequences Based on Recurrence Quantification Analysis
Current Bioinformatics Response to HAART in Treatment-Naive HIV-Infected Patients with a Prior Diagnosis of Tuberculosis or other Opportunistic Infections
Current HIV Research The Lord of the Bacteria: The Fellowship of the Leader and Other Serine Protease Inhibitors
Current Pharmaceutical Design NMR Assisted Antimicrobial Peptide Designing: Structure Based Modifications and Functional Correlation of a Designed Peptide VG16KRKP
Current Medicinal Chemistry 1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome
Current Medicinal Chemistry Nanoembedded Microparticles for Stabilization and Delivery of Drug-Loaded Nanoparticles
Current Pharmaceutical Design Drug Design for Neglected Disease in Brazil
Mini-Reviews in Medicinal Chemistry Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction
Current Vascular Pharmacology Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Aspartic Peptidases of Human Pathogenic Trypanosomatids: Perspectives and Trends for Chemotherapy
Current Medicinal Chemistry The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Structure and Function of L,D- and D,D-Transpeptidase Family Enzymes from Mycobacterium tuberculosis
Current Medicinal Chemistry Extrapulmonary Sarcoidosis: A Chameleon Disease at Imaging
Current Medical Imaging Radiolabeled Iron Oxide Nanoparticles As Dual-Modality SPECT/MRI and PET/MRI Agents
Current Topics in Medicinal Chemistry